drug
ADLYXIN
Marketedupdated 3mo agoby Sanofi-Aventis US LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(7)
approval · 7
Jul 27, 2016
approval
ADLYXIN (LIXISENATIDE) — FDA approval
ADLYXIN
→
Jul 30, 2021
approval
ADLYXIN (LIXISENATIDE) — FDA approval
ADLYXIN
→
Jun 10, 2022
approval
ADLYXIN (LIXISENATIDE) — FDA approval
ADLYXIN
→
Sep 28, 2023
approval
ADLYXIN (LIXISENATIDE) — FDA approval
ADLYXIN
→
Nov 1, 2024
approval
ADLYXIN (LIXISENATIDE) — FDA approval
ADLYXIN
→
May 28, 2025
approval
ADLYXIN (LIXISENATIDE) — FDA approval
ADLYXIN
→
Mar 12, 2026
approval
ADLYXIN (LIXISENATIDE) — FDA approval
ADLYXIN
→
Trials studying ADLYXIN
- phase4A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
- phase4iGlarLixi CGM Study in Chinese T2D Individuals After OADs
- phase2Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
- phase3iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
- phase4Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
- phase4Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes
News(1)
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.fiercebiotech · 8d ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that